Jpmorgan Chase & CO Annovis Bio, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 3,800 shares of ANVS stock, worth $25,802. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,800Holding current value
$25,802% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding ANVS
# of Institutions
45Shares Held
1.16MCall Options Held
229KPut Options Held
934K-
Vanguard Group Inc Valley Forge, PA380KShares$2.58 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il103KShares$697,2780.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$683,8140.0% of portfolio
-
Geode Capital Management, LLC Boston, MA99.1KShares$672,9840.0% of portfolio
-
Group One Trading, L.P. Chicago, IL52.8KShares$358,2870.02% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $55.4M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...